1. PRODUCT NAME

Pacimol, paracetamol 500 mg, uncoated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredient:

Paracetamol (BP) 500 mg/tablet

Excipient(s) with known effect

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

White, capsule shaped, biconvex uncoated tablet with break line on one side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

For the temporary relief of pain & discomfort, in headaches, colds and flu symptoms, rheumatic. muscular and neuralgic conditions and dental pain. Assist in reducing fever.

4.2 Dose and method of administration

Adults and children aged 12 years and over: 1 to 2 tablets every four to six hours as required. Maximum of 8 tablets in 24 hours. Maximum daily dose: 4000 mg. Children 7 to 11 years: ½ to 1 tablet every four to six hours as required. Maximum of 4 tablets in 24 hours. Do not exceed the stated dose. Adults: Do not take this medicine for longer than a few days at a time unless advised by a doctor. Children and Adolescence: Do not take this medicine for longer than 48 hours at a time unless advised by a doctor.

Not suitable for children under seven years of age. Take orally with water or other fluid. The lowest dose necessary to achieve efficacy should be used for the shortest duration of treatment. Should not be used with other paracetamol-containing products.

Minimum dosing interval: 4 hours.

4.3 Contraindications

These products are contraindicated in patients with a previous history of hypersensitivity to paracetamol or any of the excipients.

4.4 Special warnings and precautions for use

Contains paracetamol. Do not use with any other paracetamol- containing products. The concomitant use with other products containing paracetamol may lead to an overdose.

Paracetamol overdose may cause liver failure which may require liver transplant or lead to death.

Paracetamol should be used with caution in patients with:

- Impaired liver function: Underlying liver disease increases the risk of paracetamol-related liver damage
- Impaired kidney function: Administration of paracetamol to patients with moderate to severe renal impairment may result in accumulation of paracetamol conjugates.

Patients who have been diagnosed with liver or kidney impairment must seek medical advice before taking this medication. The restrictions related to the use of paracetamol products in patients with liver or kidney impairment are primarily a consequence of the paracetamol content of the drug.

Cases of hepatic dysfunction/failure have been reported in patients with depleted glutathione levels, such as those who are severely malnourished, anorexic, have a low body mass index, are chronic heavy users of alcohol or have sepsis.

In patients with glutathione depleted states the use of paracetamol may increase the risk of metabolic acidosis.

If symptoms persist, medical advice must be sought.

Keep out of sight and reach of children.

Use in children: Not recommended for children under seven years of age.

4.5 Interaction with other medicines and other forms of interaction

The following interactions with paracetamol have been noted:

The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol with increased risk of bleeding; occasional doses have no significant effect. Anticoagulant dosage may require reduction if paracetamol medication is prolonged.

Paracetamol absorption is increased by substances that increase gastric emptying, e.g. propantheline, antidepressants with anticholinergic properties and narcotic analgesics...

Paracetamol absorption is decreased by substances that decrease gastric emptying, e.g. propantheline, antidepressants with anticholinergic properties and narcotic analgesics.

Paracetamol may increase chloramphenicol concentrations.

The risk of paracetamol toxicity may be increased in patients receiving other potentially hepatotoxic drugs or drugs that induce liver microsomal enzymes such as alcohol and anticonvulsant drugs.

Paracetamol excretion may be affected and plasma concentrations altered when given with probenecid.

Colestyramine reduces the absorption of paracetamol if given within one hour of paracetamol.

4.6 Fertility, pregnancy and lactation

Use in pregnancy

As with the use of any medicine during pregnancy, pregnant women should seek medical advice before taking paracetamol.

Pregnancy Category A

Paracetamol has been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed.

Use in lactation

Paracetamol is excreted in breast milk but not in a clinically significant amount at recommended dosages. Available published data do not contraindicate breast-feeding.

4.7 Effects on ability to drive and use machines

Paracetamol is unlikely to cause an effect on the ability to drive or use machinery.

4.8 Undesirable effects

Adverse events from historical clinical trial data are both infrequent and from small patient exposure. Accordingly, events reported from extensive post-marketing experience at therapeutic/labelled dose and considered attributable are tabulated below by System Organ Class and frequency.

The following convention has been utilised for the classification of undesirable effects: very common ($\geq 1/10$), common ($\geq 1/100$), very rare ($\leq 1/10,000$), not known (cannot be estimated from available data).

Adverse event frequencies have been estimated from spontaneous reports received through post-marketing data.

Body system	Undesirable side effect	Frequency
Blood and lymphatic system disorders	Thrombocytopenia	Very rare
Immune system disorders	Anaphylaxis Cutaneous hypersensitivity reactions including, among others, skin rashes, angioedema, Stevens Johnson syndrome and Toxic Epidermal Necrolysis	Very rare
Respiratory, thoracic and mediastinal disorders	Bronchospasm, especially in patients sensitive to aspirin and other NSAIDs	Very rare
Hepatobiliary disorders	Hepatic dysfunction	Very rare

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions

https://nzphvc.otago.ac.nz/reporting/

4.9 Overdose

Experience following overdose with paracetamol indicates that the clinical signs of liver injury occur usually after 24 to 48 hours and have peaked after 4 to 6 days.

Paracetamol overdose may cause liver failure which may require liver transplant or lead to death. Acute pancreatitis has been observed, usually with hepatic dysfunction and liver toxicity.

Immediate medical management is required in the event of an overdose, even if the symptoms of overdose are not present.

If an overdose is taken or suspected, contact the Poisons Information Centre immediately for advice (0800 764 766), or the patient should go to the nearest hospital straight away. This should be done even if they feel well because of the risk of delayed, serious liver damage.

Administration of N-acetylcysteine may be required.

In cooperative adults, activated charcoal may reduce absorption of the medicine if given within one hour after ingestion.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

CAS: 103-90-2 (paracetamol)

Paracetamol MW 151.17 ATC code Paracetamol, N02BE01

Paracetamol is a para-aminophenol derivative that exhibits analgesic and anti—pyretic activity. Its mechanism of action is believed to include inhibition of prostaglandin synthesis, primarily within the central nervous system. It is given by mouth or rectally (suppositories) for mild to moderate pain and fever.

The lack of peripheral prostaglandin inhibition confers important pharmacological properties such as the maintenance of the protective prostaglandins within the gastrointestinal tract. Paracetamol is, therefore, particularly suitable for patients with a history of disease or on concomitant medication, where peripheral prostaglandin inhibition would be undesirable (such as, for example, those with a history of gastrointestinal bleeding or the elderly).

5.2 Pharmacokinetic properties

Absorption

Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract. Food intake delays paracetamol absorption.

Distribution

Paracetamol is distributed into most body tissues. Binding to the plasma proteins is minimal at therapeutic concentrations but increases with increasing doses.

Metabolism

Paracetamol is metabolised in the liver and excreted in the urine mainly as glucuronide and sulphate conjugates.

The metabolites of paracetamol include a minor hydroxylated intermediate which has hepatotoxic activity. This intermediate metabolite is detoxified by conjugation with glutathione. However, it can accumulate following paracetamol overdosage (more than 200 mg/kg or 10 g total paracetamol ingested) and, if left untreated, can cause irreversible liver damage.

Paracetamol is metabolised differently by infants and children compared to adults, the sulphate conjugate being predominant.

Excretion

Paracetamol is excreted in the urine mainly as the glucuronide and sulphate conjugates. Less than 5% is excreted as unmodified paracetamol with 85% to 90% of the administered dose eliminated in the urine within 24 hours of ingestion. The elimination half-life varies from one to three hours. The mean plasma half-life is about 2.3 hours.

5.3 Preclinical safety data

N/A

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Pregelatinised starch, sodium metabisulpite, magnesium stearate and purified water.

6.2 Incompatibilities

No known incompatibilities.

6.3 Shelf life

60 months from date of manufacture

6.4 Special precautions for storage

Store below 25°C.

6.5 Nature and contents of container

Blister pack of 1000 tablets.

6.6 Special precautions for disposal and other handling

No special requirements.

7. MEDICINE SCHEDULE

1000 tablet pack-Prescription medicine.

8. SPONSOR

Ipca Pharma (NZ) Pty Limited PO Box 74509 Auckland 1546 +64 2136 0880 in New Zealand or +61 3 98856172 in Australia

9. DATE OF FIRST APPROVAL

October 2020

10. DATE OF REVISION OF THE TEXT

July 2019

SUMMARY TABLE OF CHANGES

Section changes	Summary of new information
All sections	New